Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Transdermal System for Neurogenic Bladder in SCI
NCT00224029Phase 4Completed
- Sponsor
- Watson Pharmaceuticals
- Start
- Dec 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin in neurogenic bladder, sponsored by Watson Pharmaceuticals. Started Dec 2004; status: completed.
02
Drugs
oxybutynin
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT00224029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224029.